中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 8
Aug.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(8): 1796-1800

Influencing factors for recompensation in patients with first-time decompensated hepatitis B cirrhosis

DOI: 10.3969/j.issn.1001-5256.2022.08.015

  • Department of Infectious Diseases, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, China

Research funding:

National Science and Technology Major Project during the 13th Five-Year Plan Period (2018ZX10302-206)

More Information
  • Corresponding author: PAN Xiucheng, xzpxc68@126.com(ORCID: 0000-0001-9706-9458)
  • Received Date: 2021-12-12
  • Accepted Date: 2022-02-10
  • Published Date: 2022-08-20
    Abstract
  •   Objective  To investigate the influencing factors for recompensation in patients with first-time decompensated hepatitis B cirrhosis.  Methods  A total of 438 patients with first-time decompensated hepatitis B cirrhosis who attended The Affiliated Hospital of Xuzhou Medical University from September 1, 2011 to December 31, 2019 were enrolled, and all patients received comprehensive treatment including antiviral therapy. According to the outcome at the end of follow-up, the patients were divided into recompensation group and persistent decompensation group, and the independent influencing factors for recompensation were analyzed. Long-term survival rate was compared between the patients with different states of compensation. The Mann-Whitney U test was used for comparison of continuous data between two groups, and the chi-square test was used for comparison of categorical data. A multivariate Cox proportional-hazards regression model analysis was used to investigate the influencing factors for recompensation. The Kaplan-Meier method was used to plot survival curves, and the log-rank test was used for comparison.  Results  Among the 438 patients with decompensated hepatitis B cirrhosis, 199 (45.4%) achieved recompensation after antiviral therapy. There were significant differences between the recompensation group and the persistent decompensation group in sustained virologic response (SVR) (χ2=72.093, P < 0.001), single or multiple complications (χ2=9.834, P=0.002), presence or absence of gastrointestinal bleeding (χ2=6.346, P=0.012), serum creatinine (SCr) (Z=-1.035, P=0.011), blood sodium concentration (Z=-1.606, P=0.019), hemoglobin (Z=1.455, P=0.006), and alanine aminotransferase (ALT) level (Z=-2.194, P < 0.001). Baseline ALT level (odds ratio [OR]=1.002, 95% confidence interval [CI]: 1.000-1.003, P=0.009), SVR (OR=5.760, 95%CI: 3.634-9.129, P < 0.001), and SCr (OR=0.990, 95%CI: 0.981-1.000, P=0.047) were independent influencing factors for recompensation. The recompensation group had a significantly higher 5-year survival rate than the persistent decompensation group (87.9% vs 72.0%, χ2=9.886, P=0.025).  Conclusion  After comprehensive treatment, including antiviral therapy, approximately 45.4% of patients can achieve recompensation.Patients with elevated baseline ALT and achieved SVR were more likely to achieve recompensation, patients with elevated baseline serum creatinine had difficulty achieving recompensation, and patients with recompensation had a better long-term prognosis than patients with persistent decompensation.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    LEE HW, YIP TC, TSE YK, et al. Hepatic decompensation in cirrhotic patients receiving antiviral therapy for chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2021, 19(9): 1950-1958. e7. DOI: 10.1016/j.cgh.2020.08.064.
    [2]
    LIAW YF, SHEEN IS, LEE CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease[J]. Hepatology, 2011, 53(1): 62-72. DOI: 10.1002/hep.23952.
    [3]
    LIAW YF, RAPTOPOULOU-GIGI M, CHEINQUER H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study[J]. Hepatology, 2011, 54(1): 91-100. DOI: 10.1002/hep.24361.
    [4]
    SRIVASTAVA M, RUNGTA S, DIXIT VK, et al. Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective[J]. Antiviral Res, 2013, 100(2): 300-305. DOI: 10.1016/j.antiviral.2013.08.020.
    [5]
    Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [6]
    Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.

    中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
    [7]
    WANG LL, LU JF, ZU HM, et al. Early antiviral efficacy of tenofovir alafenamide fumarate in initial treatment of patients with hepatitis B virus-related decompensated cirrhosis[J/CD]. Chin J Liver Dis(Electr Version), 2021, 13(3): 1-8. DOI: 10.3969/j.issn.1674-7380.2021.03.001.

    王莉琳, 鲁俊锋, 祖红梅, 等. 富马酸丙酚替诺福韦初始治疗失代偿期乙型肝炎肝硬化的早期疗效[J/CD]. 中国肝脏病杂志(电子版), 2021, 13(3): 1-8. DOI: 10.3969/j.issn.1674-7380.2021.03.001.
    [8]
    WEI JN, TIAN RF, LI N, et al. Effectiveness of lamivudine combined with adefovir dipivoxil in treatment of patients with decompensated hepatitis B cirrhosis and its effects on erythrocyte distribution width and levels of inflammatory factors[J]. Med & Pharm J Chin PLA, 2021, 33(5): 84-87. DOI: 10.3969/j.issn.2095-140X.2021.09.019.

    魏娟宁, 田锐锋, 李娜, 等. 阿德福韦酯联合拉米夫定治疗对活动性代偿期乙型肝炎肝硬化患者肝功能、抗病毒效果及生存率的影响[J]. 解放军医药杂志, 2021, 33(5): 84-87. DOI: 10.3969/j.issn.2095-140X.2021.09.019.
    [9]
    XU Y, ZHANG YG, WANG X, et al. Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis[J]. World J Gastroenterol, 2015, 21(25): 7869-7876. DOI: 10.3748/wjg.v21.i25.7869.
    [10]
    SHIM JH, LEE HC, KIM KM, et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis[J]. J Hepatol, 2010, 52(2): 176-182. DOI: 10.1016/j.jhep.2009.11.007.
    [11]
    CHANG ML, CHENG JS, CHIEN RN, et al. Hepatitis flares are associated with better outcomes than no flare in patients with decompensated cirrhosis and chronic hepatitis B virus infection[J]. Clin Gastroenterol Hepatol, 2020, 18(9): 2064-2072. e2. DOI: 10.1016/j.cgh.2020.01.018.
    [12]
    YAP DY, SETO WK, FUNG J, et al. Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis[J]. Dig Liver Dis, 2017, 49(2): 202-206. DOI: 10.1016/j.dld.2016.11.001.
    [13]
    HUELIN P, PIANO S, SOLÀ E, et al. Validation of a staging system for acute kidney injury in patients with cirrhosis and association with acute-on-chronic liver failure[J]. Clin Gastroenterol Hepatol, 2017, 15(3): 438-445. e5. DOI: 10.1016/j.cgh.2016.09.156.
    [14]
    JI XX, LI L, FU JJ, et al. Influence of different virologic responses on the prognosis of patients with decompensated hepatitis B cirrhosis[J]. J Clin Hepatol, 2020, 36(5): 1033-1037. DOI: 10.3969/j.issn.1001-5256.2020.05.017.

    嵇笑笑, 李丽, 傅涓涓, 等. 不同病毒学应答状态对失代偿期乙型肝炎肝硬化患者预后的影响[J]. 临床肝胆病杂志, 2020, 36(5): 1033-1037. DOI: 10.3969/j.issn.1001-5256.2020.05.017.
    [15]
    CHEN CJ, YANG HI, SU J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J]. JAMA, 2006, 295(1): 65-73. DOI: 10.1001/jama.295.1.65.
    [16]
    JANG JW, CHOI JY, KIM YS, et al. Effects of virologic response to treatment on short- and long-term outcomes of patients with chronic hepatitis B virus infection and decompensated cirrhosis[J]. Clin Gastroenterol Hepatol, 2018, 16(12): 1954-1963. e3. DOI: 10.1016/j.cgh.2018.04.063.
    [17]
    ARAVINTHAN AD, BARBAS AS, DOYLE AC, et al. Characteristics of liver transplant candidates delisted following recompensation and predictors of such delisting in alcohol-related liver disease: a case-control study[J]. Transpl Int, 2017, 30(11): 1140-1149. DOI: 10.1111/tri.13008.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (642) PDF downloads(129) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return